228 related articles for article (PubMed ID: 16078104)
21. Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.
De Vry J; Jentzsch KR
Behav Pharmacol; 2004 Feb; 15(1):13-20. PubMed ID: 15075622
[TBL] [Abstract][Full Text] [Related]
22. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.
De Vry J; Jentzsch KR; Kuhl E; Eckel G
Behav Pharmacol; 2004 Feb; 15(1):1-12. PubMed ID: 15075621
[TBL] [Abstract][Full Text] [Related]
23. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.
Marcu JP; Christian RT; Lau D; Zielinski AJ; Horowitz MP; Lee J; Pakdel A; Allison J; Limbad C; Moore DH; Yount GL; Desprez PY; McAllister SD
Mol Cancer Ther; 2010 Jan; 9(1):180-9. PubMed ID: 20053780
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoids enhance susceptibility of immature brain to ethanol neurotoxicity.
Hansen HH; Krutz B; Sifringer M; Stefovska V; Bittigau P; Pragst F; Marsicano G; Lutz B; Ikonomidou C
Ann Neurol; 2008 Jul; 64(1):42-52. PubMed ID: 18067175
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.
Hart S; Fischer OM; Ullrich A
Cancer Res; 2004 Mar; 64(6):1943-50. PubMed ID: 15026328
[TBL] [Abstract][Full Text] [Related]
26. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro.
Bueb JL; Lambert DM; Tschirhart EJ
Biochim Biophys Acta; 2001 Apr; 1538(2-3):252-9. PubMed ID: 11336796
[TBL] [Abstract][Full Text] [Related]
27. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.
Compton DR; Gold LH; Ward SJ; Balster RL; Martin BR
J Pharmacol Exp Ther; 1992 Dec; 263(3):1118-26. PubMed ID: 1335057
[TBL] [Abstract][Full Text] [Related]
28. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells.
Galanti G; Fisher T; Kventsel I; Shoham J; Gallily R; Mechoulam R; Lavie G; Amariglio N; Rechavi G; Toren A
Acta Oncol; 2008; 47(6):1062-70. PubMed ID: 17934890
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoids Induce Cell Death and Promote P2X7 Receptor Signaling in Retinal Glial Progenitors in Culture.
Freitas HR; Isaac AR; Silva TM; Diniz GOF; Dos Santos Dabdab Y; Bockmann EC; Guimarães MZP; da Costa Calaza K; de Mello FG; Ventura ALM; de Melo Reis RA; França GR
Mol Neurobiol; 2019 Sep; 56(9):6472-6486. PubMed ID: 30838518
[TBL] [Abstract][Full Text] [Related]
30. Suppression of outward K⁺ currents by WIN55212-2 in rat retinal ganglion cells is independent of CB1/CB2 receptors.
Zhang CQ; Wu HJ; Wang SY; Yin S; Lu XJ; Miao Y; Wang XH; Yang XL; Wang Z
Neuroscience; 2013 Dec; 253():183-93. PubMed ID: 24013008
[TBL] [Abstract][Full Text] [Related]
31. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
32. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid-induced changes in respiration of brain mitochondria.
Fišar Z; Singh N; Hroudová J
Toxicol Lett; 2014 Nov; 231(1):62-71. PubMed ID: 25195527
[TBL] [Abstract][Full Text] [Related]
34. Δ
Darmani NA; Belkacemi L; Zhong W
Eur J Pharmacol; 2019 Dec; 865():172806. PubMed ID: 31738934
[TBL] [Abstract][Full Text] [Related]
35. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
36. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
Wiley JL; Lowe JA; Balster RL; Martin BR
J Pharmacol Exp Ther; 1995 Oct; 275(1):1-6. PubMed ID: 7562536
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the discriminative stimulus and response rate effects of
Wiley JL; Lefever TW; Marusich JA; Craft RM
Drug Alcohol Depend; 2017 Mar; 172():51-59. PubMed ID: 28130989
[TBL] [Abstract][Full Text] [Related]
38. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.
Roberto D; Klotz LH; Venkateswaran V
Prostate; 2019 Feb; 79(2):151-159. PubMed ID: 30242861
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid WIN-55,212-2 mesylate inhibits interleukin-1β induced matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human chondrocytes.
Dunn SL; Wilkinson JM; Crawford A; Le Maitre CL; Bunning RA
Osteoarthritis Cartilage; 2014 Jan; 22(1):133-44. PubMed ID: 24211233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
